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doi:10.1016/j.jmii.2011.01.028Background: Nigeria is a West African country of more than 150 million persons with the second
highest case of HIV/AIDS infected patients in the world. The species spectrum of oral yeast
colonization and the susceptibility to a wide range of antifungal agents is poorly understood
in Nigeria especially in the south east, south south, and the northern axis. This study evaluates
the species spectrum of oral colonization by Candida species in HIV-infected patients in Nigeria
and the in vitro susceptibility pattern of the Candida isolates to a broad range of antifungal
agents.
Methods: Two hundred oropharyngeal swabs from HIV-infected patients and 100 age-matched
healthy controls were screened for yeast isolates using standard procedures and confirmed by
the analytical profile index 20C along with other biochemical tests. In vitro susceptibility
testing of the yeast isolates to antifungals were performed using the broth microdilution
method protocol recommended by the Clinical Laboratory Scientific Institute.
Results: Of 200 patients screened, 120 (60%) were colonized by yeasts. C albicans was the
dominating species in both groups with 54 (45%) isolated from HIV subjects. The non-albicans
Candida species accounted for 55% with C tropicalis 22 (18.3%) showing the highest frequency.
We observed that 11.7% of all yeasts isolates were resistant to fluconazole, 8.3% to flucytosine,
7.5% to itraconazole, and 1.7% to voriconazole. All isolates were susceptible to amphotericin B
and most of them demonstrated very low voriconazole minimal inhibitory concentrations.
Apart from C albicans, C tropicalis and C parapsilosis isolates were also recovered from appar-
ently healthy control subjects.
Conclusion: Although C albicans continues to be the dominant Candida species in oral Candida
carriage of HIV-infected patients in Nigeria, the nonalbicans Candida species are increasing.
Furthermore, the finding of resistant isolates in our study emphasizes the need for antifungalof Dermatology, Case Western Reserve University, Cleveland, OH, USA.
o.com (E.I. Nweze).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Oral candidiasis is caused by Candida species colonizing the
oral cavity. It is the most common opportunistic fungal
infection in individuals infected with HIV and AIDS.1,2 The
risks are considered to be higher in patients with a CD4þ
cell count of less than 200 cells/mm3 and high plasma HIV
RNA loads.3,4 C albicans represents the most common
causative agent of oral candidiasis; however, other species
of Candida have begun to emerge.3 The presence of
Candida in the oral cavities of HIV/AIDS patients predicts
the subsequent development of oral candidiasis. Up till
now, no cure exists for HIV/AIDS. It then follows that
controlling opportunistic pathogens associated to this
pandemic remains one surer way of managing infected
individuals who have the scourge. To date, several Candida
species have been found to be opportunistic especially in
HIV/AIDS patients. Among them, C albicans remains the
most common. However, other species have also been
identified in the oropharyngeal cavity of HIV/AIDS
patients.5,6 The incidence of HIV/AIDS has continued to
increase globally in recent years especially in developing
countries of Africa. For instance, Africa has the world’s
highest prevalence of HIV infection, with an estimated 24.7
million adults and children older than the age of 15 years
living with HIV/AIDS in sub-Saharan Africa alone.7 Nigeria
ranks second after South Africa in the World Health Orga-
nization’s list of global HIV/AIDS prevalence. In addition,
pediatric HIV infection has been increasing in Nigeria over
the years, with 74,520 new cases estimated for 2006 alone.8
With many patients not able to buy antiretroviral drugs or
source it from government hospitals free of charge; the
death toll has significantly continued to increase. To make
matters worse, some nonenlightened individuals who get
infected often refuse to admit that they have contracted
the virus and rather think that they were given “herbal
poisons” by their enemies who live with them in local
communities and have continued to distribute this virus
among local teenagers. It becomes really difficult to access
such patients physically because symptoms, such as loss of
weight for both disease situations are similar. Other factors
such as illiteracy, lack of good health care facilities, and
use of untested herbal medicines have helped to escalate
the problem. Although some variety of studies has been
carried out on oral candidiasis in Nigeria,9,10,11 only one of
these studies11 investigated the species spectrum of oral
Candida colonization in HIV/AIDS patients. However, this
study only investigated patients in Lagos, Nigeria and
tested only fluconazole resistance of the recovered species.
Nigeria is a country of more than 150 million persons with
HIV incidence far more in the southeastern axis where our
study was undertaken. Our experience with the epidemi-
ology/etiology of other mycotic infections indicates that it
varies considerably in different parts of Nigeria apparentlybecause of its socioeconomic and geographical diver-
sity.12,13 The increasing incidence of HIV/AIDS and the rapid
migration of Nigerians to many countries in Asia, Europe,
and the United States for business reasons and other
purposes requires that the species spectrum of oral Candida
infections be known so as to provide the necessary and
required epidemiological information on the current trend
for local and international use by those concerned. Also,
the increased incidence of mucosal and probably deep
systemic forms of candidiasis has consequently made the
use of antifungal agents the best option by clinicians so as
to be able to control these pathogens. The widespread use
of these antifungals has consequently led to an increase in
antifungal resistance. Some authors have further observed
a noticeable shift toward nonalbicans species with relative
resistance to fluconazole and itraconazole.14,15 The species
spectrum and resistance of Candida isolates to currently
available antifungal drugs is therefore a highly relevant
factor because it causes important implications for
morbidity and mortality. Hence, there is a need to carry out
in vitro susceptibility tests to detect resistant organisms. In
the present study, we investigated the asymptomatic oral
carriage of Candida species in HIV-infected patients in
Nigeria and determined the in vitro susceptibility pattern
of these isolates to amphothericin B, fluconazole, flucyto-
sine, itraconazole, and voriconazole.
Most patients used in the study were sampled at
a referral health center, the Ebonyi State University
Teaching Hospital, Abakiliki, Nigeria and appropriate
permissions were obtained.Materials and methods
Patients and clinical specimens
A total of 200 oropharyngeal swabs were obtained from
HIV-infected patients (108 males and 92 females) in
southeast Nigeria. Most of these were from the Ebonyi State
University Teaching Hospital Abakiliki, Nigeria. The study
lasted for approximately 20 months. Swabs were collected
from those aged 19 years and above who were confirmed
HIV positive with suspected oropharyngeal lesions/
disorders. Swabs were taken from oral lesions when
present. The patients were all visiting for the first time.
The age- and sex-matched non-HIV subjects were recruited
from apparently healthy subjects in the population. Those
who had received treatment with antibiotics or antifungal
drugs within the last 3 weeks for therapeutic or prophy-
lactic purposes were excluded from this study.
Ninety of these patients were treated with highly active
antiretroviral therapy (HAART) that included HIV protease
inhibitor (Indinavir) and nucleoside reverse transcriptase
inhibitors (Zidovudine, Lamivudine, Nevaripin, or
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healthy age-matched subjects were included in the study
for comparative purposes. These subjects sampled were
not known to have been on any drug in the last 3 weeks
before the test. However, some of them admitted to have
taken antifungal agents in the past. A structured ques-
tionnaire was administered to each patient to obtain rele-
vant data. For the actual collection of specimens, oral
swabs were collected with a sterile swab/sterile container
respectively and inoculated onto two plates of Sabouraud
dextrose agar (SDA) (Difco Laboratories, Detroit, MI, USA)
supplemented with chloramphenicol (1 mg/mL) and incu-
bated separately 37C and 25C, respectively in ambient
air.
Identification of yeast isolates
The identification procedure of yeast isolates was per-
formed as described previously16 using morphological,
microscopic, and biochemical characteristics to confirm
cream-colored pasty colonies exhibiting characteristic
yeast smell with large gram-positive cocci, which initially
grew on SDA. Any multiple colonies were separately iden-
tified. The identified isolates were confirmed by the
analytical profile index 20C (BioMerieux, Marcy L’ Etoile,
France). Chromagar (Chromagar, Paris, France) was used
for all isolates and discrimination tests between C albicans,
C dubliniensis, and other species were investigated by
analysis of germ tube formation in calf serum at 37C for 3
hours, degree of chlamydospore production on cornmeal
agar supplemented with 1% Tween-80, colony morphology
was on Staib agar, growth at 45C on SDA, and xylose
assimilation test was carried out as previously described by
other authors.16,17 Two typed isolates C albicans American
Type Culture Collection (ATCC) 10231 and C dubliniensis
ATCC 777 were included as control.
Antifungal susceptibility testing
In vitro susceptibility testing of the yeast isolates were
performed using the broth microdilution method protocol
recommended by the Clinical Laboratory Scientific Institute
(formerly NCCLS).18 Amphotericin B (Bristol-Myers Squibb,
Princeton, NJ, USA), itraconazole (Jansen Pharmaceuticals,
Beerse, Belgium), voriconazole, flucytosine (Sigma, St
Louis, MO, USA), and fluconazole (Pfizer International, New
York, NY, USA) were tested against all the yeast isolates
recovered from the study. The final concentrations of drugs
ranged from 0.06 mg/mL to 64 mg/mL for fluconazole and
flucytosine; from 0.015 mg/mL to 16 mg/mL for amphoter-
icin B, itraconazole, and voriconazole. The medium used
was Roswell Park Memorial Institute 1640 broth with
L-glutamine without bicarbonate (GIBCO BRL, Life Tech-
nologies, California, USA) buffered to pH 7.0 with 0.165 M
3-N morpholinepropanesulfonic acid (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany) and sterilized by filtration.
The suspension of yeast cultures after 48 hours of incuba-
tion was prepared in sterile normal saline (0.85%) adjusted
using spectrophotometer at 530 nm to match the turbidity
of a 0.5 McFarland standard. This was then diluted in Ros-
well Park Memorial Institute 1640 media to obtain a finalconcentration of 1 103e5 103 colony forming units/mL.
The microplates were incubated at 35C for 48 hours.
Minimal inhibitory concentrations (MICs) were defined for
amphotericin B as the lowest concentration of drug, which
resulted in a complete inhibition of visible growth,
whereas for the three azoles and flucytosine, it was
defined as the lowest concentration of drug that produced
a 50% reduction in fungal growth compared with that one
of drug-free growth control as in Clinical and Laboratory
Standards Institute (CLSI) guidelines.18 Two quality control
isolates, C albicans ATCC 90028 and C parapsilosis ATCC
22019, were included on each day of testing to check the
accuracy of drug dilutions and the reproducibility of the
results. The purity and viability of all tested organisms
were checked by subculturing the inoculum suspension
on SDA. For determination of resistance, interpretive
susceptibility criteria for fluconazole and 5-flucytosine
were those recommended by the CLSI. For fluconazole,
isolates showing MICs 64 mg/mL were regarded as resis-
tant, whereas for 5-flucytosine, isolates showing MICs of
32 mg/mL were regarded as resistant. For voriconazole,
4 mg/mL was recently approved as the CLSI breakpoint
for resistance.19,20 Because of the lack of defined break-
points for amphotericin B, isolates showing MICs of >1 mg/mL
were considered as resistant. The Chi-squared test was
applied to analyze correlations of Candida species with
antiretroviral therapy and between infected and nonin-
fected subjects. A p value less than 0.05 was considered
statistically significant.
Results
Of 200 patients investigated, 120 of them (90 treated with
HAART) were colonized with different kinds of yeast.
Detectable growths were produced by all isolates after
incubation for 24e48 hours. C albicans had the highest
frequency among all the species with a total number of 54
(45%). The nonalbicans species and their frequencies
included C tropicalis 22 (18.3%), C parapsilosis 18 (15%),
C guilliermondii 11 (9.2%), C dubliniensis 9 (7.5%), C lusi-
taniae 2 (1.7%), C krusei 2 (1.7%), and C kefyr 2 (1.7%).
C albicans was isolated in 50 (55.6%) patients treated with
HAART and in 23 (76.7%) patients who were not on HAART.
In the age-matched control subjects, C albicans was the
major species recovered and comprised 13 and 12 isolates
from male and female subjects, respectively (Table 1).
They were all sensitive to all the five anifungals tested
against them (data not shown). C tropicalis and C para-
psilosis were also recovered from the controls subjects.
Similarly, for the nonalbicans Candida, 40 (44.4%) were
isolated from patients treated with HAART, whereas 7
(23.3%) isolates were from patients who were not on
HAART. No significant statistical association was found
between antiretroviral therapy and species of Candida
isolated in the study (pZ 0.110). There was no significant
difference between the occurrence of the species and sex
of both infected and noninfected subjects (p> 0.05). For
the 120 yeast strains, the MIC ranges were 0.015e16 mg/mL
for itraconazole, 0.125e64 mg/mL for fluconazole,
0.002e32 mg/mL for flucytosine, 0.015e8.0 mg/mL for
voriconazole, and 0.015e1.0 mg/mL for amphotericin B.
Table 1 Age and gender distribution of HIV and non-HIV infected subjects screened in the study
Age (yr) Male Female Total
HIV infected,
n (%)
Noninfected,
n (%)
HIV infected,
n (%)
Noninfected,
n (%)
HIV infected,
n (%)
Noninfected,
n (%)
19e29 27 (25) 13 (26) 14 (15.2) 8 (16) 41 (20.5) 21 (21)
30e39 25 (23) 12 (24) 29 (31.5) 14 (28) 54 (27) 26 (26)
40e49 23 (21.3) 10 (20) 25 (27.2) 16 (32) 48 (24) 26 (26)
50e59 21 (19.4) 10 (20) 15 (16.3) 9 (18) 36 (18) 19 (19)
>60 12 (11.1) 5 (10) 9 (9.8) 3 (6) 21 (10.5) 8 (8)
Total 108 (100) 50 (100) 92 (100) 50 (100) 200 (100) 100 (100)
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which 80% presented values of 0.015 mg/mL. For using the
CLSI suggested MIC interpretive criteria, we found that 14
(11.7%) of all yeasts isolates were resistant to fluconazole,
9 (7.5%) to itraconazole, 10 (8.3%) to flucytosine, and 2
(1.7%) to voriconazole. All Candida isolates were suscep-
tible to amphotericin B. C albicans was the most resistant
species (17.5%) followed by C parapsilosis (7.5%) and
C tropicalis (4.2%). On the other hand, C kefyr and C lusi-
taniae isolates showed low MICs to azoles and to ampho-
tericin B. However, C krusei particularly showed high MICs
to flucytosine and fluconazole. The MIC ranges, MICs at
which 50% (MIC50) and 90% (MIC90) of the strains were
inhibited and resistance to itraconazole, fluconazole, flu-
cytosine, amphotericin B, and voriconazole for all CandidaTable 2 Antifungal susceptibility profile of 120 oral Candida iso
Species Antifungal agents MIC ran
C albicans (nZ 54) Amphotericin B 0.015
Itraconazole 0.015
Voriconazole 0.015
Fluconazole 0.125
Flucytosine 0.12e
C tropicalis (nZ 22) Amphotericin B 0.015e
Itraconazole 0.015e
Voriconazole 0.015
Fluconazole 0.25
Flucytosine 0.12e
C parapsilosis (nZ 18) Amphotericin B 0.015
Itraconazole 0.015
Voriconazole 0.015
Fluconazole 0.125
Flucytosine 0.25e
C guilliermondii (nZ 11) Amphotericin B 0.06
Itraconazole 0.5
Voriconazole 0.015
Fluconazole 0
Flucytosine 0.12e
C dubliniensis (nZ 9) Amphotericin B 0.015
Itraconazole 0.015
Voriconazole 0.015
Fluconazole 0.125
Flucytosine 0.12
MIC defined as the lowest concentration, which resulted in no growth
itraconazole, fluconazole, and voriconazole; MIC50 and MIC90: MIC
respectively.
MICZminimal inhibitory concentration.isolates tested are shown in Table 2. The MIC ranges for the
reference strain C albicans ATCC 90028 and C parapsilosis
ATCC 22019 were within the reference range stipulated in
the CLSI guideline (data not shown).Discussion
Little is known about the etiological importance and the
species spectrum of different yeast species in the oral
colonization and infection among Nigerian HIV/AIDS
patients especially in the southeastern axis where the
population is high with higher cases of HIV/AIDS. This study
was aimed at finding out the species spectrum of Candida
species colonizing the oral cavity in HIV/AIDS patients andlates from HIV patients
ge MIC50 MIC90 Resistant number (%)
e0.5 0.125 0.5 d
e16 0.03 0.5 6 (11.1)
e8.0 0.015 0.03 1 (1.9)
e64 0.5 64 9 (16.7)
32 0.12 1.0 5 (9.3)
0.25 0.03 0.0125 d
0.25 0.015 0.125 d
e1.0 0.015 0.015 1 (7.7)
e64 4.0 4 d
32 0.5 1.0 2 (9.1)
e0.5 0.125 0.5 d
e2.0 0.03 0.5 1 (8.3)
e0.5 0.015 0.0125 d
e64 1.0 4.0 2 (11.1)
32 1.0 2.0 2 (11.1)
e1.0 0.25 1.0 d
e16 0.5 16 1 (33.3)
e1.0 0.015 0.5 d
.5e8 1.0 8.0 d
32 0.12 8.0 d
e0.5 0.125 2.0 d
e16 0.015 1.0 1 (11.1)
e8.0 0.015 1.0 d
e64 2.0 4.0 3 (33.3)
e16 1.0 8 1 (11.1)
for amphotericn B and 50% reduction in turbidity for flucytosine,
value was able to inhibit 50% and 90% of the isolates tested,
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to a wider spectrum of antifungal agents. A recent study in
Lagos, Nigeria investigated oral yeast colonization but
tested the recovered isolates for only fluconazole resis-
tance.11 Our finding of C albicans as the predominant
species is consistent with the above report but there were
some striking differences in the species spectrum and
percentage of recovered isolates. For instance, we recov-
ered a total of 54 (45%) for C albicans, 22(18.3%) of
C tropicalis, 18 (15%) of C parapsilosis, and 11 (9.2%) of
C guilliermondii. Theirs were respectively lower: 30(40.5%)
for C albicans, 13(17.6%) for C tropicalis, 3(4%) for C par-
apsilosis, and 1(1.4%) for C guillermondii. Similarly, their
study apparently could not isolate C dubliensis but this
species makes up about 7.5% of the isolates we recovered.
Although we have no immediate reasons for this observa-
tion, the level of diversity and other differences among the
various population of more than 150 million in different
regions of Nigerian could be responsible. We also observed
a similar trend (different percentage distribution and
species spectrum) in the etiology and prevalence of
dermatological infections among different geographical
regions of Nigeria.12,13 Another difference is our finding of
11.7% of Candida species resistant to fluconazole compared
with 9.5% in Lagos. Unfortunately, we are not able to
compare the resistance patterns to the rest of the other
drugs because their study tested only fluconazole suscep-
tibility. However, our findings on C albicans as the most
prevalent species agrees with other published reports from
different parts of the world.5,21,22 Although this contrasts
with the observation in some countries in the Gulf region,23
it is similar to the findings reported from Brazilian HIV/AIDS
patients.5 In Europe, North America and Australia, C albi-
cans usually accounts for 60e80% of yeasts isolated from
the mouth of healthy persons. However, oral mycobiota
varies from country to country and C albicans is not always
the predominant species.15 Studies of epidemiologic
surveillance have showed that the proportion of non-
albicans species is increasing among the HIV-infected
patients.5 In our study, although C albicans was the
predominant species, the nonalbicans species represented
55% of all the isolates recovered in the study. This is much
higher than 42.1% reportedly isolated from the same
category of patients in Brazil.5 Nonalbicans species play
an important role as causative agents in oropharyngeal
candidiasis and have been associated with severe symp-
toms.5 Medicines, such as antibacterial antibiotics, anti-
retroviral, and antifungal agents can interfere in changes in
the species distribution.18 In patients who have not taken
protease inhibitors, C albicans has been most common than
nonalbicans.5 This is consistent with our finding of C albi-
cans as the major species recovered from the age-matched
control normal subjects. We have noted that although the
percentage of C albicans isolates has been higher in non-
treated patients with HAART than in the treated ones,
there were no significant association between antiretroviral
therapy and Candida species (pZ 0.110). Although the
frequency is different, the isolation of C dubliniensis in our
study is similar to the published observations in the United
States and Brazil5,22,24 but in contrast to another Brazilian
study.5 We were unable to isolate C glabrata that has
been considered an emerging pathogen. Although it wasrecovered in the Lagos study, it constituted only a small
fraction (5.4%) of the total isolates recovered in that study,
suggesting that it may not be very common in the oral flora
of HIV-infected subjects in Nigeria. It may be difficult to
explain the reason for the variability in our frequency of the
Candida species with those of other authors.
Our result on in vitro susceptibility of Candida species to
amphotericin B is consistent with those reported previ-
ously5,25 and shows that Candida isolates recovered in the
study were highly sensitive to polyene antifungal, ampho-
tericin B. The MIC distribution was concentrated in a very
narrow range. Although it has been suggested that C lusi-
taniae isolates may present innate resistance to ampho-
tericin B,5 the two recovered C lusitaniae isolates showed
MIC of 0.25 mg/mL and was categorized as susceptible to
amphotericin B according to the interpretative breakpoints
adopted in our study. These results confirm those of Pfaller
et al.19 who noted that primary resistance to amphotericin
B was not very common among C lusitaniae isolates. The
introduction of effective antiretroviral therapy has no
doubt made a tremendous impact on the natural history of
HIV infections and its management, especially reducing the
incidence of oropharyngeal candidiasis and a trend toward
less-frequent in vitro resistance to fluconazole.5 Unfortu-
nately, our study showed that fluconazole resistance was
relatively high in the HIV-infected group. We found that
12.31% of Candida isolates were resistant in vitro to flu-
conazole (MIC 64 mg/mL). Conversely, all the species
recovered from the age-matched control groups were
susceptible to all the antifungals tested. Factors, such as
the degree of immunosuppression of the patients, the
chemotherapeutic drugs use, and the intrinsic resistance of
Candida species5 may contribute to fluconazole resistance.
In our study, 15 (16.7%) of the isolates obtained from 90
patients who used HAART were resistant to fluconazole and
4 (13.3%) of the isolates identified from 30 patients who did
not receive HAART were resistant to this drug. Candida
isolates were generally more susceptible to voriconazole
than to itraconazole. Also, 12.5% of our isolates were
resistant to flucytosine. Both observations agree with those
ones verified by other researchers.5,15,22
Despite the fact that C albicans continues to be present
in most yeast carriage from oral mucosa of HIV-infected
patients in Nigeria, its frequency may vary, with a recent
trend to nonalbicans species. Our study shows that the
species of nonalbicans were isolated in 55% of the patients.
All isolates were susceptible to amphotericin B, which has
been the first choice of treatment for severe fungal infec-
tions for more than several decades. However, its use has
been limited by a number of serious adverse effects. Vor-
iconazole presented potent activity against Candida sp,
including those that were resistant to fluconazole and
itraconazole isolates. Because voriconazole is well toler-
ated, it could be used against Candida infections caused by
strains resistant to fluconazole and itraconazole. Unfortu-
nately, this drug is not very commonly available in Nigeria
and accessibility may be poor. We agree that surveillance
programs are needed to identify possible changes in the
species distribution and antifungal susceptibility patterns
of yeasts peculiar to each region or country as a way of
monitoring the trend and ensuring better management of
HIV/AIDS patients.
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